CNN Examines Aggressive Form Of Breast Cancer That Disproportionately Affects Black Women

CNN on Wednesday reported on triple negative breast cancer, a "rare, fast-moving cancer that has experts ... stumped." Nearly 50% of black women under age 55 who are diagnosed with breast cancer have the triple negative type, compared with 15% of all women with breast cancer.

International Study Of Sagopilone Shows Promise In Some Cases Of Advanced Prostate Cancer

Men with a certain type of prostate cancer have been shown to respond to a new chemotherapy drug, Sagopilone, plus prednisone in an international trial led by Oregon Health & Science University Cancer Institute researchers.The research involved men with androgen-independent prostate cancer that has metastasized, meaning their cancer has spread beyond the prostate and is not longer responding to hormonal therapies.

Rivaroxaban Phase III Pivotal Data Presented At EFORT Annual Meeting

Results from a pivotal Phase III clinical trial demonstrate that rivaroxaban, an oral, once-daily, investigational anticoagulant medication, was superior in preventing venous blood clots in patients who underwent total knee replacement (TKR) surgery.

Eribulin Mesylate Demonstrated Anti-Tumor Activity In Patients With Advanced Breast Cancer

The investigational chemotherapeutic agent eribulin mesylate (E7389) demonstrated activity in a heavily pretreated population of women with locally advanced or metastatic breast cancer, according to results of a multi-center Phase II clinical trial. The study also suggests that eribulin mesylate has a manageable tolerability profile, with a low incidence of Grade 3 (severe) and no Grade 4 (disabling or life-threatening) neuropathy.

Rivaroxaban Shows Consistent Results Across Phase III Clinical Trial RECORD Programme

Phase III clinical trial results demonstrate that rivaroxaban (Xarelto ), a one tablet/once-daily, oral investigational anticoagulant, showed superior efficacy in preventing venous blood clots in patients following total knee replacement (TKR), whilst maintaining low major bleeding rates.

PTC124 Featured At Third Annual Congress Of Myology - PTC Announces Initiation Of Additional Phase 2b Clinical Trial Sites In Europe

PTC Therapeutics, Inc. (PTC) announced that PTC124, the company's orally delivered investigational new drug for the treatment of genetic disorders due to nonsense mutations, was featured in a symposium at Myology 2008, the Third Annual Congress of Myology, on Friday, May 30 in Marseilles.

Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial For Atopic Dermatitis

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT) has begun Phase 2 clinical testing of PH-10, the company's topical drug for dermatology, for the treatment of atopic dermatitis, a chronic skin condition that includes some forms of eczema. The study is designed to evaluate efficacy of PH-10 in a total of twenty subjects with mild to severe forms of the disease.

InterMune Announces Start Of 14-Day Triple Combination Study Of ITMN-191 In Patients With Chronic Hepatitis C

InterMune, Inc. (Nasdaq: ITMN) announced that it has begun dosing in its Phase 1b clinical trial evaluating ITMN-191, designated R7227 at Roche (SWX: ROG), in combination with Pegasys(R) (pegylated interferon alpha-2a) and Copegus(R) (ribavirin) in treatment-naive patients infected with chronic hepatitis C virus (HCV) genotype 1 infection.

Viropharma Announces Completion Of Enrollment In Phase 3 Study Of Maribavir In Stem Cell Transplant Patients

ViroPharma Incorporated (Nasdaq: VPHM) announced that it completed enrollment in its pivotal Phase 3 study of maribavir in stem cell transplant patients. This international Phase 3 study is evaluating the efficacy, safety and tolerability of prophylactic use of maribavir administered orally for up to 12 weeks for the prevention of cytomegalovirus (CMV) disease in recipients of allogeneic stem cell transplants (SCT).

Favrille Announces Results From Phase 3 Registration Trial Of Specifid In Patients With Follicular B-Cell Non Hodgkin's Lymphoma

Favrille, Inc. (Nasdaq: FVRL) announced results from the Company's Phase 3 registration trial of Specifid(TM) following Rituxan(R) in patients with follicular B-cell non-Hodgkin's lymphoma (NHL).